Proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs. The company’s lead product (LEVADEX) is an orally inhaled migraine therapy.
In March 2013, MAP was acquired by Allergan (NYSE: AGN).